Manager TitleAgeSince
Chief Executive Officer 61 01/04/2013
Director TitleAgeSince
Chairman 61 19/07/2018
Director/Board Member 66 31/12/2021
Date Insider Type Main position Quantity % Market Cap.
31/08/23Buy

Director

30,876 0.9978%
31/08/23Buy

Chief Executive Officer

20,586 0.6653%
31/08/23Buy

Chief Financial Officer

30,876 0.9978%
Change 5-day change 1-year change 3-year change Capi.($)
-99.00%-.--% - - 4
-0.46%-0.09%-21.01%+2.72% 121B
+0.37%-5.03%-2.19%-13.68% 12.28B
-1.57%-0.14%+34.19%+93.19% 8.2B
+3.39%+2.33%-47.97%-71.63% 3.87B
+2.37%+0.94%+16.83%+37.61% 2.51B
+2.95%+5.16%-10.98%-13.42% 1.81B
+2.50%+1.70%-4.87%-24.74% 1.58B
+0.33%-3.72%+232.84%+162.52% 1.57B
Average -9.90%+1.09%+24.60%+21.57% 19.07B
Weighted average by Cap. -0.23%-0.12%-13.68%+6.13%
Logo Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Company’s flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.
Employees
8
  1. Stock Market
  2. Stocks
  3. ARTHQ Stock